GlassScriptPhysician profile
Michael A Franklin
NPI 1548277189
$20,002.06
in general payments reported to CMS, 2019-2025
62 companies · $2,067 in 2025
The $2,067 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $7,694 · 2021: $3,818 · 2022: $250 · 2023: $2,030 · 2024: $2,401 · 2025: $2,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,497.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,506.97 | 2019-2021 | |
| Abbvie INC. | $2,853.36 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $686.99 | 2019-2025 | |
| Pfizer INC. | $565.96 | 2023-2025 | |
| Ge Healthcare | $515.32 | 2019-2024 | |
| Ucb, INC. | $419.08 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Alexion Pharmaceuticals, INC. | $399.98 | 2019-2024 | Ultomiris, Soliris |
| Biogen, INC. | $391.72 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Takeda Pharmaceuticals U.S.A., INC. | $360.23 | 2023-2025 | Hyqvia, Gammagard |
| Lilly USA, LLC | $328.38 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Lundbeck LLC | $297.71 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $270.36 | 2019-2025 | Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $267.71 | 2019-2025 | Ocrevus, Evrysdi |
| Argenx US, INC. | $267.36 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $230.73 | 2019-2025 | Uplizna |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.